Drug discovery

Synthetic DNA
#AI #Antibodies #Biotechnology #Drug development #Drug discovery #Synthetic biology #Synthetic DNA #Synthetic libraries

Synthetic biology tools advancing and accelerating drug discovery efforts

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery.  The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Read More

#Exclusive Content

Neurons in the brain
#Drug discovery #In vitro assays #Multiple sclerosis #Neurodegenerative disorders #Neuronal damage #Target identification #Webinar

Webinar: Innovative assays for neurodegeneration drug discovery

Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this new on-demand webinar we use multiple sclerosis as a case-study… Read More

Webinar date:
Brought to you by Malvern Panalytical
#News

Neurons in the brain
#Drug discovery #In vitro assays #Multiple sclerosis #Neurodegenerative disorders #Neuronal damage #Target identification #Webinar

Innovative assays for neurodegeneration drug discovery programs

Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this on-demand webinar, presented by Dr Elise Malavasi, Principal Scientist at… Read More

Webinar date:
Brought to you by Malvern Panalytical
#Webinars

#Biotechnology #Drug development #Drug discovery #Genomics #Synthetic biology #Synthetic DNA

Synthetic biology: Shaping the future of drug discovery 

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research… Read More

#Exclusive Content #Trends & Analysis

World Diabetes Day
#Diabetes #Drug discovery #Type 1 diabetes #Type 2 diabetes #World Diabetes Day

World Diabetes Day: Five drug discovery developments 

For World Diabetes Day, DDW’s Diana Spencer provides an overview of the latest innovations in the treatment of the disease. Here are 2022’s five most significant discoveries (in no particular order):  1. Human beta cell model Earlier this year, Human Cell Design, a biotechnology company focused on… Read More

#Exclusive Content #News #Trending News

#Cancer #Cancer research #Carbon emissions #Covid-19 #Drug development #Drug discovery #Graft vs Host Disease #Monkeypox #Sustainability

Latest industry updates for the DDW Highlights series

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we learned the shocking statistic that… Read More

#News

#Cancer #Cancer research #Carbon emissions #Covid-19 #Drug development #Drug discovery #Graft vs Host Disease #Monkeypox #Sustainability

This week in drug discovery (7-11 November)

News round-up for 7-11 November by DDW Digital Content Editor Diana Spencer  This week we learned the shocking statistic that a third of scientific researchers have, or know a close colleague who has, experienced abuse after posting research online.  It wasn’t all bad news, however, as top… Read More

#News

#CAR-T #Drug discovery #eBook #Immuno-oncology

Latest eBook: Innovation in immuno-oncology

This 28-page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many pathways Access… Read More

#News

#AI #Drug development #Drug discovery #Enzymes #Metabolomics

AI development duo to advance drug-metabolising enzymes 

Optibrium and Lhasa, developers of software and artificial intelligence (AI) solutions for drug discovery and development, have published a peer-reviewed study, Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning, where the team combined existing experimental results, quantum mechanics and… Read More

#Business & Investment #News

Builders checking plans
#Biologics / Biotechnology #Biotech hubs #Cell and gene therapy #Drug discovery #Expansion #Investment #Laboratory #Manufacturing

Space to innovate: where are biotech’s top expansions?

Expansions to laboratory space throughout the drug discovery industry can only be a good thing – new centres of innovation will bring more space to grow, more advanced technologies, improved sustainability and new employment opportunities.  While there have been a significant number of new facilities built in the US,… Read More

#Editor's Choice #News

#Drug discovery #Patent Law #Pharmaceuticals #Regulatory

Navigating the growing labyrinth of pharma disputes 

Michael Frisby, Partner at Stevens & Bolton LLP, examines where legal disputes are likely to occur within the pharmaceutical industry.  The current economic environment has fuelled fears of recession and with it a rise in disputes. But where are disputes likely to arise for… Read More

#Regulatory

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

AI brain
#AI / data analytics / healthtech / informatics #ALS #Biotechnology #Clinical trials #Drug discovery #Genomics

AI-driven biotech initiates Phase I trial for ALS drug 

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor… Read More

#News

#Drug development #Drug discovery #Guide #Hit to lead #Hit-finding #Lead optimisation

Latest guide: Hit-finding strategies for potent and specific molecules

This new guide is brought to you by Eurofins Discovery. Download the guide to hit-finding tools that will accelerate your hit to lead and lead optimisation programmes for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity… Read More

#News

Eurofins Guide
#Drug development #Drug discovery #Guide #Hit to lead #Hit-finding #Lead optimisation

Hit-finding strategies for potent and specific molecules

Download the guide for hit-finding tools that will accelerate your hit to lead and lead optimisation programs for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity and focused libraries Small molecule and biologics targeted screening for GPCRs, kinases, ion… Read More

#Resources